17.10.2023 14:26:27
|
Beyond Cancer Presents Pre-clinical Data On Combination Of UNO And Anti-mPD-1
(RTTNews) - Beyond Cancer announced the publication of pre-clinical data showing that the combination of ultra-high concentration Nitric Oxide and Anti-mPD-1 therapy improved tumor regression rates and survival in mice. The data were published in an article entitled, Intratumoral Administration of High-Concentration Nitric Oxide and Anti-mPD-1 Treatment Improves Tumor Regression Rates and Survival in CT26 Tumor-Bearing Mice.
The company noted that first-in-human phase 1 clinical study is ongoing with initial data anticipated to be released on November 3.
Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (XAIR), is a development-stage biopharmaceutical and medical device company utilizing ultra-high concentration nitric oxide via a proprietary delivery platform to treat primary tumors and prevent metastatic disease.
For More Such Health News, visit rttnews.com.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Beyond Airmehr Nachrichten
10.11.24 |
Ausblick: Beyond Air stellt das Zahlenwerk zum vergangenen Quartal vor (finanzen.net) |